Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

Background The development of systemic treatment options leveraging the molecular
landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Follicular thyroid carcinoma (FTC) and benign follicular adenoma (FA) are indistinguishable
by preoperative diagnosis due to their similar histological features. Here we report the first …

Context: Thyroid nodules are common in adults, but only a small fraction of them is
malignant. Fine-needle aspiration (FNA) cytology provides a definitive diagnosis of benign …

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

Objectives: Next-generation sequencing (NGS) allows for high-throughput sequencing
analysis of large regions of the human genome. We explored the use of targeted NGS for …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Activating point mutations of the BRAF gene have been recently reported in papillary thyroid
carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell …